Jennifer R Donnan1, Catherine A Grandy1, Eugene Chibrikov1, Carlo Marra PharmD1, Kris Aubrey-Bassler1, Karissa Johnston1, Michelle Swab1, Jenna Hache1, Daniel Curnew1, Hai Nguyen1, John-Michael Gamble2. 1. School of Pharmacy (Donnan, Grandy, Chibrikov, Marra, Johnston, Hache, Curnew, Nguyen, Gamble) and Faculty of Medicine (Aubrey-Bassler, Swab), Memorial University, St. John's, NL; School of Pharmacy (Marra), University of Otago, Dunedin, New Zealand; School of Pharmacy (Gamble), University of Waterloo, Kitchener, Ont. 2. School of Pharmacy (Donnan, Grandy, Chibrikov, Marra, Johnston, Hache, Curnew, Nguyen, Gamble) and Faculty of Medicine (Aubrey-Bassler, Swab), Memorial University, St. John's, NL; School of Pharmacy (Marra), University of Otago, Dunedin, New Zealand; School of Pharmacy (Gamble), University of Waterloo, Kitchener, Ont. jm.gamble@uwaterloo.ca.
Abstract
BACKGROUND: The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose-response relation between SGLT2 inhibitors and urinary tract infections (UTIs) in patients with type 2 diabetes, relative to other diabetes therapies or placebo. METHODS: We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of SGLT2 inhibitors in patients with type 2 diabetes. We searched 6 databases and the reference lists of key papers. We included studies with placebo or active antidiabetic comparators that reported the outcome of UTI, and established thresholds for high and low doses of SGLT2 inhibitors. We used a random-effects model to estimate the pooled effect estimates and 95% credible intervals. RESULTS: We screened 2418 citations and included 105 references for studies of 8 unique SGLT2 inhibitors, representing 60 082 individuals (with a total of 4348 UTIs). Most mixed-treatment comparisons showed no significant difference in risk of UTI, with the exception of high-dose dapagliflozin (≥ 10 mg) compared with placebo (odds ratio [OR] 1.30, 95% credible interval 1.09-1.57), with active comparators (OR 1.44, 95% credible interval 1.15-1.79), with empagliflozin at both low (OR 1.30, 95% credible interval 1.04-1.60) and high (OR 1.39, 95% credible interval 1.12-1.72) doses, and with low-dose ertugliflozin (OR 1.43, 95% credible interval 1.01-2.01). When the analysis was restricted to RCTs with a low risk of bias, the results were nonsignificant. INTERPRETATION: Current RCT evidence does not suggest a dose-response relation between most SGLT2 inhibitors and UTIs, with the exception of dapagliflozin. Further research is needed to quantify the relation between SGLT2 inhibitors and more serious infections. TRIAL REGISTRATION: PROSPERO registration no. CRD42016038715. Copyright 2018, Joule Inc. or its licensors.
BACKGROUND: The sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel group of drugs for treatment of type 2 diabetes mellitus. We investigated whether there is a dose-response relation between SGLT2 inhibitors and urinary tract infections (UTIs) in patients with type 2 diabetes, relative to other diabetes therapies or placebo. METHODS: We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of SGLT2 inhibitors in patients with type 2 diabetes. We searched 6 databases and the reference lists of key papers. We included studies with placebo or active antidiabetic comparators that reported the outcome of UTI, and established thresholds for high and low doses of SGLT2 inhibitors. We used a random-effects model to estimate the pooled effect estimates and 95% credible intervals. RESULTS: We screened 2418 citations and included 105 references for studies of 8 unique SGLT2 inhibitors, representing 60 082 individuals (with a total of 4348 UTIs). Most mixed-treatment comparisons showed no significant difference in risk of UTI, with the exception of high-dose dapagliflozin (≥ 10 mg) compared with placebo (odds ratio [OR] 1.30, 95% credible interval 1.09-1.57), with active comparators (OR 1.44, 95% credible interval 1.15-1.79), with empagliflozin at both low (OR 1.30, 95% credible interval 1.04-1.60) and high (OR 1.39, 95% credible interval 1.12-1.72) doses, and with low-dose ertugliflozin (OR 1.43, 95% credible interval 1.01-2.01). When the analysis was restricted to RCTs with a low risk of bias, the results were nonsignificant. INTERPRETATION: Current RCT evidence does not suggest a dose-response relation between most SGLT2 inhibitors and UTIs, with the exception of dapagliflozin. Further research is needed to quantify the relation between SGLT2 inhibitors and more serious infections. TRIAL REGISTRATION: PROSPERO registration no. CRD42016038715. Copyright 2018, Joule Inc. or its licensors.
Authors: Jason T Alexander; Erin M Staab; Wen Wan; Melissa Franco; Alexandra Knitter; M Reza Skandari; Shari Bolen; Nisa M Maruthur; Elbert S Huang; Louis H Philipson; Aaron N Winn; Celeste C Thomas; Meltem Zeytinoglu; Valerie G Press; Elizabeth L Tung; Kathryn Gunter; Brittany Bindon; Sanjay Jumani; Neda Laiteerapong Journal: J Gen Intern Med Date: 2021-11-30 Impact factor: 6.473
Authors: Shrita Patel; Anne Hickman; Robert Frederich; Susan Johnson; Susan Huyck; James P Mancuso; Ira Gantz; Steven G Terra Journal: Diabetes Ther Date: 2020-05-05 Impact factor: 2.945